Promising Phase 2a Data Sends Immuneering (IMRX) Stock Soaring 55%

Immuneering Corporation (NASDAQ:IMRX) stock soared 55% on Thursday after the company announced promising data from its ongoing Phase 2a trial of IMM-1-104 in pancreatic cancer.

Immuneering shares promising IMM-1-104 data

The most striking results were observed when IMM-1-104 was combined with modified gemcitabine/nab-paclitaxel, a widely used first-line treatment for pancreatic cancer. This combination achieved an overall response rate (ORR) of 43%, which notably surpassed the benchmark ORR of 23% reported in the Phase 3 MPACT study for gemcitabine/nab-paclitaxel alone. Moreover, the disease control rate (DCR) for this combination was 86%, compared to 48% in the MPACT study.

Dr. Ben Zeskind, CEO of Immuneering, expressed optimism regarding these promising results, stating that the company is positioning IMM-1-104 for future pivotal clinical trials based on this data.

“These compelling Phase 2a data continue to support the potential of IMM-104 to significantly improve treatment outcomes for patients with pancreatic cancer,” said Dr. Zeskind.

IMM-1-104 combo with mFFX shows tumor shrinkage

In addition to the combination with gemcitabine/nab-paclitaxel, Immuneering also disclosed positive initial data from the combination of IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients.

Importantly, all evaluable patients in this arm experienced shrinkage of target lesions, with one patient achieving a 100% reduction. This response to IMM-1-104 highlights its potential to substantially benefit pancreatic cancer patients.

Furthermore, IMM-1-104 monotherapy in second-line pancreatic cancer patients showed a 67% reduction in target lesions, adding to the evidence of the compound’s clinical activity.

IMM-1-104 boasts differentiated tolerability, Fast Track status

IMM-1-104’s differentiated tolerability profile is also noteworthy, with the treatment expected to be better tolerated than currently approved MEK inhibitors for similar uses, which could lead to better patient outcomes and adherence.

The treatment has already received Fast Track designation from the FDA for its use in first- and second-line pancreatic cancer, as well as for unresectable or metastatic NRAS-mutant melanoma. This designation will expedite the development process, enabling faster approval if the results continue to demonstrate efficacy.

Immuneering plans to initiate three new Phase 2a combination arms in 2025, with expanded trials in melanoma and non-small cell lung cancer (NSCLC) also planned.

The positive data and plans for continued clinical development sparked renewed investor interest, propelling the company’s stock price higher.

Expert commentary on Immuneering’s Phase 2a data

Dr. Tanios Bekaii-Saab of the Mayo Clinic Cancer Center commented on the Phase 2a data, praising IMM-1-104 for its potential to improve both efficacy and tolerability in first-line pancreatic cancer treatment.

“These Phase 2a data demonstrate the potential of IMM-104 to improve both the efficacy and tolerability of first-line therapy for patients with pancreatic cancer,” said Dr. Bekaii-Saab.

“The high overall response rate and disease control rate observed with IMM-104 in combination with modified gemcitabine/nab-paclitaxel are particularly encouraging,” he added, highlighting the broader promise of IMM-104, which is being evaluated in different cancer types due to its well-tolerated nature.

With further updates from the IMM-1-104 Phase 2a trials expected in the second quarter of 2025, the excitement surrounding the compound’s clinical potential continues to build. Immuneering’s progress will be closely followed, as it could bring much-needed innovation to the treatment of pancreatic cancer and other difficult-to-treat malignancies.